好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Adult Onset Multiple Acyl-CoA Dehydrogenase Deficiency (MADD) Diagnostic Challenge
Neuromuscular and Clinical Neurophysiology (EMG)
P17 - Poster Session 17 (11:45 AM-12:45 PM)
11-008

To report two cases of adult-onset myopathy due to Multiple acyl-CoA Dehydrogenase Deficiency (MADD).

MADD is a rare, autosomal-recessive disorder of fatty acid oxidation. Although late-onset MADD is described, it remains a diagnostic challenge.  Diagnosis is complex requiring concordant findings from muscle biopsy, acylcarnitine profiling, urine organic acids and identification of pathogenic variants in ETFAETFB, or ETFDH genes.

Case Report.

Case 1: 46-year-old female with one year of muscle aches and exercise intolerance. Initial examination showed normal muscle strength. CK was mildly elevated, and EMG showed non-irritable myopathy. Muscle biopsy showed increased lipid droplets in type 1 muscle fibers without necrosis or inflammation. Quantitative serum acylcarnitine profiling showed several elevated acylcarnitines with low serum carnitine levels. Genetic testing showed heterozygosity with a pathogenic variant in ETFDH, c.1601C>T (p.Pro534Leu). She was treated with riboflavin and L-carnitine with some improvement in symptoms.

 

Case 2: 37-year-old female with two years of proximal muscle aches and exercise intolerance. She had elevated CK levels. Reportedly she had a normal EMG and muscle biopsy. A repeat EMG showed non-irritable myopathy. Repeat muscle biopsy showed increased lipid droplets in type 1 muscle fibers without necrosis or inflammation. A quantitative serum acylcarnitine profiling showed several elevated acylcarnitines. Quantitative urine acylglycine profile was abnormal. Genetic testing showed she was heterozygous for pathogenic variants in CPT2, c.388C>T (p.Ser113Leu) and ETFDH, c.413T>G (p.Leu138Arg), and heterozygous for a VUS in ETFA, c.295A>G (p.Thr99Ala). Biochemical profile is more consistent with MADD than CPTII.

These are two cases of MADD presenting as adult-onset myopathy. Our patients are heterogeneous for pathogenic variants, yet manifest symptoms in adulthood with histologic and biochemical profiles consistent with MADD. It is possible that a second variant was missed by genetic testing but demonstrates the need for multiple concordant findings for diagnosis.

Authors/Disclosures
Jory Liang, MD (Ohio state university)
PRESENTER
Dr. Liang has nothing to disclose.
Jennifer A. Roggenbuck, MS, CGC (Ohio State University) The institution of Ms. Roggenbuck has received research support from Packard Foundation.
Sarah Heintzman, NP (The Ohio State University) Ms. Heintzman has nothing to disclose.
Bakri Elsheikh, MD, FAAN (The Ohio State University Wexner Medical Center) Dr. Elsheikh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen . Dr. Elsheikh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argnex . The institution of Dr. Elsheikh has received research support from Biogen. The institution of Dr. Elsheikh has received research support from Cure SMA.
Adam Quick, MD (The Ohio State University) The institution of Dr. Quick has received research support from NINDS. The institution of Dr. Quick has received research support from NEALS.